The former cofounder of Knome believes that the future of precision medicine lies in our ability to program living things to act as medicines.
The firm recognized revenues in fiscal Q1 2019 of $11.5 million, driven by rapid growth in its NGS products as well as its synthetic biology business.
The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.
Ohio State University researchers found that a phosphorothioate-modified DNA-crRNA duplex completely blocked the function of Cas12a.
Aside from its core synthetic biology business, the company has expanded into NGS and is looking to move into drug discovery and DNA data storage.
Twist, which went public in October, reported that its revenues doubled this year due to increased sales of its synthetic DNA products and the introduction of NGS products.
CNGB was founded by the Chinese government and BGI to collect genomics technologies and resources, and promote their use by the research community.
Cowen gave the company a rating of Outperform while JP Morgan assigned its shares a Neutral rating.
The French startup plans to offer a precommercial version of its hardware platform to beta testers as early as the end of 2019.
Eurofins will distribute Synthego's sgRNA products to its customers in 44 countries.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.